News | January 31, 2022
Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
Subscribe To Our Newsletter & Stay Updated
